Long-term Treatment with Low-Dose Caffeine Worsens BPSD-Like Profile in 3xTg-AD Mice Model of Alzheimer’s Disease and Affects Mice with Normal Aging
Coffee or caffeine has recently been suggested as prophylaxis for dementia. Although memory problems are hallmarks of Alzheimer’s disease, this dementia is also characterized by neuropsychiatric symptoms called Behavioral and Psychological Symptoms of Dementia (BPSD). The impact of preventive/therap...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2018-02-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | http://journal.frontiersin.org/article/10.3389/fphar.2018.00079/full |
id |
doaj-adb787df983346f5a034d1722142e57a |
---|---|
record_format |
Article |
spelling |
doaj-adb787df983346f5a034d1722142e57a2020-11-24T22:53:20ZengFrontiers Media S.A.Frontiers in Pharmacology1663-98122018-02-01910.3389/fphar.2018.00079330402Long-term Treatment with Low-Dose Caffeine Worsens BPSD-Like Profile in 3xTg-AD Mice Model of Alzheimer’s Disease and Affects Mice with Normal AgingRaquel Baeta-Corral0Raquel Baeta-Corral1Björn Johansson2Björn Johansson3Lydia Giménez-Llort4Lydia Giménez-Llort5Institut de Neurociències, Universitat Autònoma de Barcelona, Barcelona, SpainDepartment of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Barcelona, SpainDepartment of Molecular Medicine and Surgery, Karolinska Institutet, Solna, SwedenDepartment of Geriatrics, Karolinska University Hospital, Solna, SwedenInstitut de Neurociències, Universitat Autònoma de Barcelona, Barcelona, SpainDepartment of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Barcelona, SpainCoffee or caffeine has recently been suggested as prophylaxis for dementia. Although memory problems are hallmarks of Alzheimer’s disease, this dementia is also characterized by neuropsychiatric symptoms called Behavioral and Psychological Symptoms of Dementia (BPSD). The impact of preventive/therapeutic strategies on both cognitive and non-cognitive symptoms can be addressed in the 3xTg-AD mice, since they exhibit cognitive but also BPSD-like profiles. Here, we studied the long-term effects of a low dose of caffeine in male 3xTg-AD mice and as compared to age-matched non-transgenic (NTg) counterparts with normal aging. Animals were treated (water or caffeine in drinking water) from adulthood (6 months of age) until middle-aged (13 months of age), that in 3xTg-AD mice correspond to onset of cognitive impairment and advanced stages, respectively. The low caffeine dosing used (0.3 mg/ml) was previously found to give a plasma concentration profile in mice roughly equivalent to that of a human coffee drinker. There were significant effects of caffeine on most behavioral variables, especially those related to neophobia and other anxiety-like behaviors, emotionality, and cognitive flexibility. The 3xTg-AD and NTg mice were differently influenced by caffeine. Overall, the increase of neophobia and other anxiety-related behaviors resulted in an exacerbation of BPSD-like profile in 3xTg-AD mice. Learning and memory, strongly influenced by anxiety in 3xTg-AD mice, got little benefit from caffeine, only shown after a detailed analysis of navigation strategies. The worsened pattern in NTg mice and the use of search strategies in 3xTg-AD mice make both groups more similar. Circadian motor activity showed genotype differences, which were found to be enhanced by caffeine. Selective effects of caffeine on NTg were found in the modulation of behaviors related to emotional profile and risk assessment. Caffeine normalized splenomegaly of 3xTg-AD mice, a physical indicator of their impaired peripheral immune system, and trended to increase their corticosterone levels. Our observations of adverse caffeine effects in an Alzheimer’s disease model together with previous clinical observations suggest that an exacerbation of BPSD-like symptoms may partly interfere with the beneficial cognitive effects of caffeine. These results are relevant when coffee-derived new potential treatments for dementia are to be devised and tested.http://journal.frontiersin.org/article/10.3389/fphar.2018.00079/fullaginganxietymemoryNPSBPSDcircadian activity |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Raquel Baeta-Corral Raquel Baeta-Corral Björn Johansson Björn Johansson Lydia Giménez-Llort Lydia Giménez-Llort |
spellingShingle |
Raquel Baeta-Corral Raquel Baeta-Corral Björn Johansson Björn Johansson Lydia Giménez-Llort Lydia Giménez-Llort Long-term Treatment with Low-Dose Caffeine Worsens BPSD-Like Profile in 3xTg-AD Mice Model of Alzheimer’s Disease and Affects Mice with Normal Aging Frontiers in Pharmacology aging anxiety memory NPS BPSD circadian activity |
author_facet |
Raquel Baeta-Corral Raquel Baeta-Corral Björn Johansson Björn Johansson Lydia Giménez-Llort Lydia Giménez-Llort |
author_sort |
Raquel Baeta-Corral |
title |
Long-term Treatment with Low-Dose Caffeine Worsens BPSD-Like Profile in 3xTg-AD Mice Model of Alzheimer’s Disease and Affects Mice with Normal Aging |
title_short |
Long-term Treatment with Low-Dose Caffeine Worsens BPSD-Like Profile in 3xTg-AD Mice Model of Alzheimer’s Disease and Affects Mice with Normal Aging |
title_full |
Long-term Treatment with Low-Dose Caffeine Worsens BPSD-Like Profile in 3xTg-AD Mice Model of Alzheimer’s Disease and Affects Mice with Normal Aging |
title_fullStr |
Long-term Treatment with Low-Dose Caffeine Worsens BPSD-Like Profile in 3xTg-AD Mice Model of Alzheimer’s Disease and Affects Mice with Normal Aging |
title_full_unstemmed |
Long-term Treatment with Low-Dose Caffeine Worsens BPSD-Like Profile in 3xTg-AD Mice Model of Alzheimer’s Disease and Affects Mice with Normal Aging |
title_sort |
long-term treatment with low-dose caffeine worsens bpsd-like profile in 3xtg-ad mice model of alzheimer’s disease and affects mice with normal aging |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Pharmacology |
issn |
1663-9812 |
publishDate |
2018-02-01 |
description |
Coffee or caffeine has recently been suggested as prophylaxis for dementia. Although memory problems are hallmarks of Alzheimer’s disease, this dementia is also characterized by neuropsychiatric symptoms called Behavioral and Psychological Symptoms of Dementia (BPSD). The impact of preventive/therapeutic strategies on both cognitive and non-cognitive symptoms can be addressed in the 3xTg-AD mice, since they exhibit cognitive but also BPSD-like profiles. Here, we studied the long-term effects of a low dose of caffeine in male 3xTg-AD mice and as compared to age-matched non-transgenic (NTg) counterparts with normal aging. Animals were treated (water or caffeine in drinking water) from adulthood (6 months of age) until middle-aged (13 months of age), that in 3xTg-AD mice correspond to onset of cognitive impairment and advanced stages, respectively. The low caffeine dosing used (0.3 mg/ml) was previously found to give a plasma concentration profile in mice roughly equivalent to that of a human coffee drinker. There were significant effects of caffeine on most behavioral variables, especially those related to neophobia and other anxiety-like behaviors, emotionality, and cognitive flexibility. The 3xTg-AD and NTg mice were differently influenced by caffeine. Overall, the increase of neophobia and other anxiety-related behaviors resulted in an exacerbation of BPSD-like profile in 3xTg-AD mice. Learning and memory, strongly influenced by anxiety in 3xTg-AD mice, got little benefit from caffeine, only shown after a detailed analysis of navigation strategies. The worsened pattern in NTg mice and the use of search strategies in 3xTg-AD mice make both groups more similar. Circadian motor activity showed genotype differences, which were found to be enhanced by caffeine. Selective effects of caffeine on NTg were found in the modulation of behaviors related to emotional profile and risk assessment. Caffeine normalized splenomegaly of 3xTg-AD mice, a physical indicator of their impaired peripheral immune system, and trended to increase their corticosterone levels. Our observations of adverse caffeine effects in an Alzheimer’s disease model together with previous clinical observations suggest that an exacerbation of BPSD-like symptoms may partly interfere with the beneficial cognitive effects of caffeine. These results are relevant when coffee-derived new potential treatments for dementia are to be devised and tested. |
topic |
aging anxiety memory NPS BPSD circadian activity |
url |
http://journal.frontiersin.org/article/10.3389/fphar.2018.00079/full |
work_keys_str_mv |
AT raquelbaetacorral longtermtreatmentwithlowdosecaffeineworsensbpsdlikeprofilein3xtgadmicemodelofalzheimersdiseaseandaffectsmicewithnormalaging AT raquelbaetacorral longtermtreatmentwithlowdosecaffeineworsensbpsdlikeprofilein3xtgadmicemodelofalzheimersdiseaseandaffectsmicewithnormalaging AT bjornjohansson longtermtreatmentwithlowdosecaffeineworsensbpsdlikeprofilein3xtgadmicemodelofalzheimersdiseaseandaffectsmicewithnormalaging AT bjornjohansson longtermtreatmentwithlowdosecaffeineworsensbpsdlikeprofilein3xtgadmicemodelofalzheimersdiseaseandaffectsmicewithnormalaging AT lydiagimenezllort longtermtreatmentwithlowdosecaffeineworsensbpsdlikeprofilein3xtgadmicemodelofalzheimersdiseaseandaffectsmicewithnormalaging AT lydiagimenezllort longtermtreatmentwithlowdosecaffeineworsensbpsdlikeprofilein3xtgadmicemodelofalzheimersdiseaseandaffectsmicewithnormalaging |
_version_ |
1725663730192089088 |